Writing 5 min read

Closing the AI Governance Gap: A Validation Playbook

Most health systems deploy AI faster than they validate it. A five-step playbook to close the gap.

Closing the AI Governance Gap: A Validation Playbook

Photo by Leeloo The First on Pexels

The short answer

Most health systems deploy AI faster than they validate it: in a KLAS and UPMC study, 93 percent were using third-party AI but only 44 percent had a dedicated environment to test it. Closing that gap, in my experience, means standing up an AI validation function: inventory every model, define acceptance criteria (CHAI-style model cards make good ones), validate locally in shadow mode before go-live, monitor for drift, and name an owner who can turn a model off. I treat those model-card criteria as CI/CD test cases so validation runs on every change, not once at purchase.

Healthcare has an AI adoption problem in reverse. The tools are everywhere; the validation is not. In a KLAS and UPMC study, ninety-three percent of health systems reported using third-party AI, but only forty-four percent had a dedicated environment to test it. That gap, in my experience, is where trust goes to die: a model that no one validated locally will eventually make a confident, wrong call on a real patient.

Closing the gap is not a policy memo. It is a function you stand up, with steps, owners, and tests that run on every change. This is the playbook I use.

The gap: everyone deploys, few validate

I start by looking honestly at the numbers, because they describe most organizations, including yours. Deployment has outrun the infrastructure to govern it, and testing before purchase is not the same as validating on your own patients.

93%
of health systems use third-party AI
44%
have a dedicated environment to validate it
92%
say they test third-party tools before deployment
52%
deploy clinical documentation tools, the most common use

Ninety-two percent say they test third-party tools before deployment, yet fewer than half have a dedicated place to do it. That combination usually means testing is a slide deck from the vendor, not a run on local data. The fix I push is to make validation a capability you own.

Stand up a validation function

A validation function is five repeatable steps. None of them are exotic. The discipline is doing them for every model, including the ones that arrived switched on inside a product you already bought.

01

Inventory every AI in use

Built or bought, and where each one touches a decision.

02

Set acceptance criteria per model

Use CHAI-style model cards: intended use, data, performance, and limits.

03

Validate locally in shadow mode

Run on your patients and your data before it acts.

04

Wire monitoring from day one

Track drift, overrides, and outcomes, not just accuracy.

05

Name an owner who can turn it off

Write the kill criteria before go-live.

The step I watch teams skip is the last one. If no one is allowed to turn a model off, you do not have governance, you have hope. Name the owner and write the kill criteria before go-live, while everyone is still calm.

Turn model cards into CI/CD test criteria

A model card is only paper until it becomes a test. The CHAI-style fields, intended use, performance, known limits, and subgroup behavior, map cleanly onto test cases, and once they are tests they run on every change instead of once at purchase. That is how I keep a model honest after the launch demo.

Model card fieldTest criterionRuns when
Intended useInputs match the approved use caseOn every prompt or config change
Performance claimMeets your local accuracy and latency barOn every model version
Known limitsGuardrails block out-of-scope inputsOn every release
Subgroup behaviorNo material gap across key groupsOn a schedule and on data shifts

This is what turns governance from an annual review into continuous assurance. A prompt change, a model upgrade, or a data shift all trip the same tests, and a failure blocks the release the way a failed unit test blocks a merge.

What to monitor after go-live

Validation does not end at go-live; it changes shape. The job becomes watching for the slow failures: quiet accuracy drift, rising override rates, and inputs that no longer look like the training data. Each needs a metric, a cadence, and an owner.

MetricWhy it mattersCadence
Local accuracy vs baselineCatches silent degradationContinuous
Override rateClinicians voting with their clicksWeekly
Input driftUpstream data has changedContinuous
Incident and near-miss logFeeds the decision to turn it offPer event

I package these steps and tests as a checklist my team runs every release, the same way a pilot runs a preflight. Wire it into evaluation and guardrails and human-in-the-loop review, and the gap between deploying AI and trusting it starts to close. A downloadable validation checklist can hang off this page as a companion resource.

Key takeaways
  • Deployment has outrun validation: 93 percent of systems use AI, only 44 percent have a place to test it.
  • Stand up a validation function with five steps: inventory, acceptance criteria, shadow validation, monitoring, and an owner who can turn it off.
  • Testing before purchase is not the same as validating on your own patients and data.
  • Turn CHAI-style model cards into CI/CD test cases so validation runs on every change.
  • After go-live, monitor accuracy drift, override rate, and input drift, each with a cadence and an owner.

Frequently asked

What is AI governance in a health system?

The function that decides which AI is deployed, proves it is safe on local data, monitors it after launch, and can turn it off. It is more than a policy document.

What does the 93 percent versus 44 percent gap mean?

Almost every system uses third-party AI, but fewer than half have a dedicated environment to validate it, so much of that AI runs without local testing.

What is a model card and why turn it into tests?

A model card documents intended use, performance, and limits. Turning those into automated test cases makes validation run on every change instead of once at purchase.

What is shadow mode?

Running a model silently on real cases without acting on its output, so you can measure local performance before it touches a patient.

Who should own AI validation?

A named owner with the authority to block a release and turn a live model off, plus written kill criteria agreed before go-live.

Sources

Naveen Kumar

Naveen Kumar

Healthcare engineering and product executive in Pittsburgh. 15+ years building AI-first patient access, a decade at Treatspace.

Read next